CM 4620

Drug Profile

CM 4620

Alternative Names: CM-4620

Latest Information Update: 25 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CalciMedica
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Immunosuppressants; ORAI1 protein inhibitors; STIM1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pancreatitis

Most Recent Events

  • 24 May 2017 CM 4620 receives Fast Track designation for Pancreatitis [Parenteral] in USA
  • 06 Jan 2017 Phase-I clinical trials in Pancreatitis (In volunteers) in USA (Parenteral)
  • 14 Nov 2016 CalciMedica plans phase II trial of CM 4620 for Pancreatitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top